Global Immuno Oncology Market Overview And Scope:
Global Immuno Oncology Market Size was estimated at USD 50274.14 million in 2022 and is projected to reach USD 116584.74 million by 2028, exhibiting a CAGR of 15.05% during the forecast period.
The Global Immuno Oncology Market Report 2025 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Immuno Oncology utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2025 and 2032. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
Top Key Players Mentioned Are: Bristol-Myers Squibb, Merck and Co., Inc., Roche AG, AstraZeneca, Plc, Sanofi S.A., Dendreon Pharmaceuticals, Novartis, Gilead Sciences Inc., Merck KGaA
Global Immuno Oncology Market Segmentation
By Type, Immuno Oncology market has been segmented into:Immune Checkpoint Inhibitors
Cytokine-Based Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy
Others
Immuno-
By Application, Immuno Oncology market has been segmented into:
Hospitals
Drugstores
Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Immuno Oncology market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Immuno Oncology market.
Top Key Players Covered in Immuno Oncology market are:
Bristol-Myers Squibb
Merck and Co.
Inc.
Roche AG
AstraZeneca
Plc
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
Merck KGaA
Objective to buy this Report:
1. Immuno Oncology analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Immuno Oncology market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Immuno Oncology Market by Type
5.1 Immuno Oncology Market Overview Snapshot and Growth Engine
5.2 Immuno Oncology Market Overview
5.3 Immune Checkpoint Inhibitors
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Immune Checkpoint Inhibitors: Geographic Segmentation
5.4 Cytokine-Based Immunotherapy
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Cytokine-Based Immunotherapy: Geographic Segmentation
5.5 Cancer Vaccines
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Cancer Vaccines: Geographic Segmentation
5.6 CAR-T Cell Therapy
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 CAR-T Cell Therapy: Geographic Segmentation
5.7 Others
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Others: Geographic Segmentation
5.8 Immuno-
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size (2017-2032F)
5.8.3 Key Market Trends, Growth Factors and Opportunities
5.8.4 Immuno-: Geographic Segmentation
Chapter 6: Immuno Oncology Market by Application
6.1 Immuno Oncology Market Overview Snapshot and Growth Engine
6.2 Immuno Oncology Market Overview
6.3 Hospitals
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hospitals: Geographic Segmentation
6.4 Drugstores
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Drugstores: Geographic Segmentation
6.5 Others
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Others: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Immuno Oncology Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Immuno Oncology Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Immuno Oncology Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 BRISTOL-MYERS SQUIBB
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 MERCK AND CO.
7.4 INC.
7.5 ROCHE AG
7.6 ASTRAZENECA
7.7 PLC
7.8 SANOFI S.A.
7.9 DENDREON PHARMACEUTICALS
7.10 NOVARTIS
7.11 GILEAD SCIENCES INC.
7.12 MERCK KGAA
Chapter 8: Global Immuno Oncology Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Immune Checkpoint Inhibitors
8.2.2 Cytokine-Based Immunotherapy
8.2.3 Cancer Vaccines
8.2.4 CAR-T Cell Therapy
8.2.5 Others
8.2.6 Immuno-
8.3 Historic and Forecasted Market Size By Application
8.3.1 Hospitals
8.3.2 Drugstores
8.3.3 Others
Chapter 9: North America Immuno Oncology Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Immune Checkpoint Inhibitors
9.4.2 Cytokine-Based Immunotherapy
9.4.3 Cancer Vaccines
9.4.4 CAR-T Cell Therapy
9.4.5 Others
9.4.6 Immuno-
9.5 Historic and Forecasted Market Size By Application
9.5.1 Hospitals
9.5.2 Drugstores
9.5.3 Others
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Immuno Oncology Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Immune Checkpoint Inhibitors
10.4.2 Cytokine-Based Immunotherapy
10.4.3 Cancer Vaccines
10.4.4 CAR-T Cell Therapy
10.4.5 Others
10.4.6 Immuno-
10.5 Historic and Forecasted Market Size By Application
10.5.1 Hospitals
10.5.2 Drugstores
10.5.3 Others
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Immuno Oncology Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Immune Checkpoint Inhibitors
11.4.2 Cytokine-Based Immunotherapy
11.4.3 Cancer Vaccines
11.4.4 CAR-T Cell Therapy
11.4.5 Others
11.4.6 Immuno-
11.5 Historic and Forecasted Market Size By Application
11.5.1 Hospitals
11.5.2 Drugstores
11.5.3 Others
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Immuno Oncology Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Immune Checkpoint Inhibitors
12.4.2 Cytokine-Based Immunotherapy
12.4.3 Cancer Vaccines
12.4.4 CAR-T Cell Therapy
12.4.5 Others
12.4.6 Immuno-
12.5 Historic and Forecasted Market Size By Application
12.5.1 Hospitals
12.5.2 Drugstores
12.5.3 Others
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Immuno Oncology Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Immune Checkpoint Inhibitors
13.4.2 Cytokine-Based Immunotherapy
13.4.3 Cancer Vaccines
13.4.4 CAR-T Cell Therapy
13.4.5 Others
13.4.6 Immuno-
13.5 Historic and Forecasted Market Size By Application
13.5.1 Hospitals
13.5.2 Drugstores
13.5.3 Others
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Immuno Oncology Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Immune Checkpoint Inhibitors
14.4.2 Cytokine-Based Immunotherapy
14.4.3 Cancer Vaccines
14.4.4 CAR-T Cell Therapy
14.4.5 Others
14.4.6 Immuno-
14.5 Historic and Forecasted Market Size By Application
14.5.1 Hospitals
14.5.2 Drugstores
14.5.3 Others
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Immuno Oncology Scope:
|
Report Data
|
Immuno Oncology Market
|
|
Immuno Oncology Market Size in 2025
|
USD XX million
|
|
Immuno Oncology CAGR 2025 - 2032
|
XX%
|
|
Immuno Oncology Base Year
|
2024
|
|
Immuno Oncology Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Bristol-Myers Squibb, Merck and Co., Inc., Roche AG, AstraZeneca, Plc, Sanofi S.A., Dendreon Pharmaceuticals, Novartis, Gilead Sciences Inc., Merck KGaA.
|
|
Key Segments
|
By Type
Immune Checkpoint Inhibitors
Cytokine-Based Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy
Others
Immuno-
By Applications
Hospitals
Drugstores
Others
|
